Abstract��OBJECTIVE To prepare amphiphilic polycaprolactone-poly (arginine polymer) (PCL-R15)/siRNA Nanopexes, and two kinds of nanoparticles with different particle size were prepared by different process. After encapsulated siRNA with electrostatic interaction, both of two nanoplexes (NR60/siRNA and NR160/siRNA) were used to compare the effects in vitro cell levels. METHODS The particle size and Zeta potential, siRNA loading and protection ability, cytotoxicity, cellular uptake mechanism and gene silencing efficiency of the two nanoplexes were investigated. RESULTS The RESULTS show that the two nanoplexes have similar siRNA protection ability and cytotoxicity, but the difference between the two sizes is about 100 nm and the potential difference is about 20 mV. Moreover, NR160/siRNA complexes have higher cell uptake efficiency, more complex uptake pathways, and show greater gene silencing efficiency. CONCLUSION These nanoplexes with different particle sizes can cause different transfection efficiency for siRNA delivery in cells.
������,��ƮƮ,����֮,�����. ��ͬ�����Ʊ���PCL-R15/siRNA����������������ѧЧӦ�Ƚ�����[J]. �й�ҩѧ��־, 2017, 52(22): 1998-2006.
LIU Wei-zhong, LI Piao-piao, YU Min-zhi, WANG Jian-cheng. Comparative Evaluations of in Vitro Biological Effects of PCL-R15/siRNA Nanoplexes Prepared by Different Processes. Chinese Pharmaceutical Journal, 2017, 52(22): 1998-2006.
OH Y K, PARK T G. siRNA delivery systems for cancer treatment[J]. Adv Drug Deliv Rev, 2009, 61(10):850-862.
[2]
OZPOLAT B, SOOD A K, LOPEZ-BERESTEIN G. Liposomal siRNA nanocarriers for cancer therapy[J]. Adv Drug Deliv Rev, 2014, 66:110-116.
[3]
AAGAARD L, ROSSI J J. RNAi therapeutics:principles, prospects and challenges[J]. Adv Drug Deliv Rev, 2007, 59(2-3):75-86.
[4]
MIELE E, SPINELLI G P, MIELE E, et al. Nanoparticle-based delivery of small interfering RNA:challenges for cancer therapy[J]. Int J Nanomed, 2012, 7:3637-3657.
[5]
ZHAO X, PAN F, HOLT C M, et al. Controlled delivery of antisense oligonucleotides:a brief review of current strategies[J]. Expert Opin Drug Deliv, 2009, 6(7):673-686.
[6]
WHITEHEAD K A, LANGER R, ANDERSON D G. Knocking down barriers:advances in siRNA delivery[J]. Nat Rev Drug Discov, 2009, 8:129-138.
[7]
ZHANG J, LI X, HUANG L. Non-viral nanocarriers for siRNA delivery in breast cancer[J]. J Controlled Release, 2014, 190:440-450.
[8]
CHOI K Y, SILVESTRE O F, HUANG X, et al. A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo[J]. Nat Prot, 2014, 9(8):1900-1915.
[9]
ZHU W J, YANG S D, QU C X, et al. Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor[J]. Int J Nanomed, 2017, 12:3375-3393.
[10]
SUN T, ZHANG Y S, PANG B, et al. Engineered nanoparticles for drug delivery in cancer therapy[J]. Angewandte Chemie, 2014, 53(46):12320-12364.
[11]
YU Y, QIU L. Optimizing particle size of docetaxel-loaded micelles for enhanced treatment of oral epidermoid carcinoma[J]. Nanomed:Nanotechnol Biol Med, 2016, 12:1941-1949.
[12]
PERRAULT S D, WALKEY C, JENNINGS T, et al. Mediating tumor targeting efficiency of nanoparticles through design[J]. Nano Lett, 2009, 9(5):1909-1915.
[13]
DREHER M R, LIU W, MICHELICH C R, et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers[J]. J Nati Cancer Inst, 2006, 98(5):335-344.
[14]
HUANG K, MA H, LIU J, et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo[J]. ACS Nano, 2012, 6(5):4483-4493.
[15]
LEE H, FONGE H, HOANG B, et al. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles[J]. Mol Pharm, 2010, 7(4):1195-1208.
[16]
CHAN A T, LEWIS J A. Size ratio effects on interparticle interactions and phase behavior of microsphere-nanoparticle mixtures[J]. Langmuir:ACS J Surfaces Colloids, 2008, 24(20):11399-11405.
[17]
DASH B C, RETHORE G, MONAGHAN M, et al. The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility[J]. Biomaterials, 2010, 31(32):8188-8197.
[18]
HE C, HU Y, YIN L, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles[J]. Biomaterials, 2010, 31(13):3657-3666.
[19]
LAI S K, HIDA K, MAN S T, et al. Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway[J]. Biomaterials, 2007, 28(18):2876-2884.
[20]
JETTE K K, LAW D, SCHMITT E A, et al. Preparation and drug loading of poly(ethylene glycol)-block-poly(epsilon-caprolactone) micelles through the evaporation of a cosolvent azeotrope[J]. Pharm Res, 2004, 21(7):1184-1191.
[21]
FUTAKI S. Membrane-permeable arginine-rich peptides and the translocation mechanisms[J]. Adv Drug Deliv Rev, 2005, 57(4):547-558.
[22]
WANG S, AMORNWITTAWAT N, JUWITA V, et al. Arginine, a key residue for the enhancing ability of an antifreeze protein of the beetle dendroides canadensis[J]. Biochemistry, 2009, 48(40):9696-9703.
[23]
HONG J, LI Y, LI Y, et al. Annonaceous acetogenins nanosuspensions stabilized by PCL-PEG block polymer:significantly improved antitumor efficacy[J]. Int J Nanomedi, 2016, 11:3239-3253.
[24]
EFTEKHARI H, JAHANDIDEH A, ASGHARI A, et al. Assessment of polycaprolacton (PCL) nanocomposite scaffold compared with hydroxyapatite (HA) on healing of segmental femur bone defect in rabbits[J]. Artificial Cells, Nanomed Biotechnol, 2016,45(5):961-968.
[25]
DONG X, CHEN H, QIN J, et al. Thermosensitive porphyrin-incorporated hydrogel with four-arm PEG-PCL copolymer (��):doxorubicin loaded hydrogel as a dual fluorescent drug delivery system for simultaneous imaging tracking in vivo[J]. Drug Deliv, 2017, 24(1):641-650.
[26]
BERNABEU E, GONZALEZ L, LEGASPI M J, et al. Paclitaxel-loaded TPGS-b-PCL nanoparticles:in vitro cytotoxicity and cellular uptake in MCF-7 and MDA-MB-231 cells versus mPEG-b-PCL nanoparticles and abraxane(R) [J]. J Nanosci Nanotechnol, 2016, 16(1):160-170.
[27]
ALMEIDA A, SILVA D, GONCALVES V, et al. Synthesis and characterization of chitosan-grafted-polycaprolactone micelles for modulate intestinal paclitaxel delivery[J]. Drug Deliv Trans Res, 2017, DOI:10.1007/S13346-017-0357-8.
[28]
WIN K Y, FENG S S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs[J]. Biomaterials, 2005, 26(15):2713-2722.
2017, Vol. 52 
